Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

UniMark Pharmaceuticals Pvt. Ltd.

Private pharmaceutical manufacturer · Rawat · Pakistan

Rawat/Islamabad pharmaceutical manufacturer and marketing-authorisation holder represented in current DRAP product and GMP records.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date25 Aug 2026Newest effective date among published current price records
Corporate profile evidence1 sourceCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Private pharmaceutical manufacturer
Address
Plot No. 7-A, Street No. S-7, National Industrial Zone, Rawat, Islamabad, Pakistan
Corporate source details checked
16 Aug 2026
Corporate profile completeness
50%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000557 Unimark Pharmaceuticals. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000557 51 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx57public portfolio records represented
REG53unique registrations represented
IDX51indexed MedInfoBase presentations
SRC1additional source-observed presentations
R+5registry-only registrations
VER5registry-verified exact registrations
PKR51current validated price records
G29generic molecules in indexed catalogue
DF7dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage89%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage80%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixUniMark Pharmaceuticals Pvt. Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/unimark-pharmaceuticals-pvt-ltdGenerated 24 Sep 2026Anti-infectives23 · 45%Cardiovascular11 · 22%Pain & musculoskeletal3 · 6%Endocrine & metabolic3 · 6%Vitamins, minerals & nutrition3 · 6%Hematology & thrombosis2 · 4%Gastrointestinal & hepatology2 · 4%Other therapeutic areas4 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioUniMark Pharmaceuticals Pvt. Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/unimark-pharmaceuticals-pvt-ltdGenerated 24 Sep 202651presentationsTablet30 · 59%Capsule7 · 14%Injection7 · 14%Cream2 · 4%Gel2 · 4%Suspension2 · 4%Other forms1 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionUniMark Pharmaceuticals Pvt. Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/unimark-pharmaceuticals-pvt-ltdGenerated 24 Sep 202641comparable productsBelow peer median12 · 29%Near peer median16 · 39%Above peer median13 · 32%Company median price position+2.7%Lowest-price equivalents1Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsUniMark Pharmaceuticals Pvt. Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/unimark-pharmaceuticals-pvt-ltdGenerated 24 Sep 2026Zafa Pharmaceutical Laboratories (P…20 shared69% overlapPulse Pharmaceuticals (Pvt.) Ltd.20 shared69% overlapNabiqasim Industries (Pvt) Ltd.,19 shared66% overlapBarrett Hodgson Pakistan (Pvt.) Ltd19 shared66% overlapMediate Pharmaceutical Pvt Ltd18 shared62% overlapNovaMed Pharmaceuticals(Pvt.)Ltd18 shared62% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives23 products · 45%
Cardiovascular11 products · 22%
Pain & musculoskeletal3 products · 6%
Endocrine & metabolic3 products · 6%
Vitamins, minerals & nutrition3 products · 6%
Hematology & thrombosis2 products · 4%
Gastrointestinal & hepatology2 products · 4%
Dermatology1 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins7 products · 14%
Fluoroquinolone antibacterials7 products · 14%
Nitrates / antianginals7 products · 14%
Macrolide antibacterials4 products · 8%
Analgesics / NSAIDs3 products · 6%
Antidiabetic medicines3 products · 6%
Vitamins / minerals / hematinics3 products · 6%
Antiplatelet medicines2 products · 4%
Formulation footprint

Dosage forms

Tablet30 products
Capsule7 products
Injection7 products
Cream2 products
Gel2 products
Suspension2 products
Lotion1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ElvisCeftriaxone 5presentations 1 g, 250 mg, 500 mg · Injection #2 AlbaParacetamol 3presentations 500 mg · Tablet #3 Mong 400Moxifloxacin 2presentations 400 mg · Tablet #4 NACCholecalciferol 2presentations 5 mg, 5 mg/mL · Injection #5 NiglysNitroglycerin 2presentations 2.6 mg, 6.4 mg · Capsule #6 Niglys S.RNitroglycerin 2presentations 2.6 mg, 6.4 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1229% of comparable products
Near market median16within ±5% of median
Above market median1332% of comparable products
Lowest-price equivalents1ties included
Company median price position +2.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Mong 400 400 mgMoxifloxacin · Tablet · 5's PKR 91.86/tablet-50.2% vs market median Mong 400 400 mgMoxifloxacin · Tablet · 1x10 PKR 94.75/tablet-48.6% vs market median Oliza 250 250 mgLevofloxacin · Tablet · 1x10 PKR 33.91/tablet-29.7% vs market median Glimicron 80 mgGliclazide · Tablet · 2x10 PKR 9.08/tablet-19.9% vs market median Cupid 250 (Klax) 250 mgClarithromycin · Tablet · 1x10 PKR 39.89/tablet-16.1% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 20shared generics Pulse Pharmaceuticals (Pvt.) Ltd.116 products · 48 generics 20shared generics Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 19shared generics Barrett Hodgson Pakistan (Pvt.) Ltd187 products · 63 generics 19shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 18shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 18shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers47Distinct registrations among indexed, published, presentation-validated products only
Verified price observations93
Products with a verified price51
Products with multiple price observations42
Source records with multiple versions51
Latest portfolio source check22 Sep 2026
Latest effective price date25 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

53 unique registration(s) · 51 indexed presentation(s) · 1 additional source-observed presentation(s) · 5 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Alba Paracetamol 500 mg Tablet 3x10 036021 PKR 105.71 PKR 3.52/tablet Near median
Alba Paracetamol 500 mg Tablet 10x10 036021 PKR 592.42 PKR 5.92/tablet 64% above median
Alba Paracetamol 500 mg Tablet 2x10 036021 PKR 70.47 PKR 3.52/tablet Near median
Angipro Acetylsalicylic acid (Aspirin) 75 mg Tablet 3x10 063020 PKR 54.03 PKR 1.80/tablet 12% below median
Benfor 1.25 Glibenclamide + Metformin 1.25 mg + 250 mg Tablet 3x10 036031 PKR 89.27 PKR 2.98/tablet No comparator
Benfor 2.5 Glibenclamide + Metformin 2.5 mg + 500 mg Tablet 2x10 036030 PKR 92.70 PKR 4.64/tablet No comparator
Carsel 25 Metoprolol Tartrate 25 mg Tablet 3x10 024368 PKR 140.94 PKR 4.70/tablet No comparator
Cidic-H Fusidic acid + Hydrocortisone acetate 2% + 1% Cream 15mg 066631 PKR 289.23 — No comparator
Clinxer Clindamycin 10 mg/mL Lotion 30ml 036048 PKR 216.16 PKR 7.21/mL Near median
Clinxer V Clindamycin 2% Cream 40gm 049147 PKR 541.41 PKR 13.54/g 7% above median
Cupid 250 (Klax) Clarithromycin 250 mg Tablet 1x10 038006 PKR 398.94 PKR 39.89/tablet 16% below median
Cupid 500 (Klax) Clarithromycin 500 mg Tablet 1x10 038007 PKR 757.99 PKR 75.80/tablet 10% below median
Depagor-20 Fluoxetine 20 mg Capsule 3x10 056158 PKR 351.51 PKR 11.72/capsule 10% below median
Elvis Ceftriaxone 1 g IV injection 1's 121417 PKR 662.96 PKR 662.96/vial/unit 12% above median
Elvis Ceftriaxone 500 mg IV injection 1's 121418 PKR 351.10 PKR 351.10/vial/unit 12% above median
Elvis Ceftriaxone 500 mg IM injection 1's 121419 PKR 351.10 PKR 351.10/vial/unit 6% above median
Elvis Ceftriaxone 250 mg Injection 1's 121420 PKR 208.60 PKR 208.60/vial/unit 9% above median
Elvis Ceftriaxone 250 mg Injection 1's 121421 PKR 208.60 PKR 208.60/vial/unit 9% above median
Elvis Injection 2gm IVRegistry verified Ceftriaxone — — — 132434Official source ↗ No indexed price — —
Geomet V Metronidazole 0.75 % Gel 25gm 049172 PKR 179.52 PKR 7.18/g No comparator
Giza Artemether + Lumefantrine 20 mg + 120 mg Tablet 2x8 055172 PKR 638.31 PKR 39.89/tablet Near median
Glimicron Gliclazide 80 mg Tablet 2x10 036032 PKR 181.52 PKR 9.08/tablet 20% below median
Hemobest Iron polymaltose complex + Folic acid 100 mg + 0.35 mg Tablet 3x10 036050 PKR 414.91 PKR 13.83/tablet Near median
Jax-50 Clomifene citrate 50 mg Tablet 10's 066630 PKR 444.92 PKR 44.49/tablet 7% above median
Jesper-50 Losartan 50 mg Tablet 2x10 066626 PKR 411.97 PKR 20.60/tablet Near median
Jesper-Plus Losartan + Hydrochlorothiazide 50 mg + 12.5 mg Tablet 2x10 066627 PKR 617.95 PKR 30.90/tablet Near median
Jits 40mg InjectionRegistry verified Esomeprazole as Sodium — — — 129851Official source ↗ No indexed price — —
Kaisen 250 Ciprofloxacin 250 mg Tablet 1x10 054791 PKR 259.31 PKR 25.93/tablet Near median
Kaisen 500 Ciprofloxacin 500 mg Tablet 1x10 054792 PKR 428.86 PKR 42.89/tablet Near median
Lignocain Lidocaine 2% Gel 15gm 036049 PKR 30.90 PKR 2.06/g 11% below median
Magnex 1gm InjectionRegistry verified Cefoperazone as Sodium, Sulbactum as Sodium — — — 124975Official source ↗ No indexed price — —
Magnex 2g InjectionRegistry verified Cefoperazone as Sodium, Sulbactum as Sodium — — — 124974Official source ↗ No indexed price — —
Miodarone Amiodarone 200 mg Tablet 3x10s 066628 PKR 398.94 PKR 13.30/tablet Near median
Mong 400 Moxifloxacin 400 mg Tablet 5's 056174 PKR 459.31 PKR 91.86/tablet 50% below median
Mong 400 Moxifloxacin 400 mg Tablet 1x10 056174 PKR 947.48 PKR 94.75/tablet 49% below median
Monosor 20 Isosorbide mononitrate 20 mg Tablet 2x10 036023 PKR 153.59 PKR 7.68/tablet 7% above median
Monosor 40 Isosorbide mononitrate 40 mg Tablet 2x10 036024 PKR 245.35 PKR 12.27/tablet 5% below median
Monosor XL Isosorbide mononitrate 60 mg Tablet 3x10 036025 PKR 478.73 PKR 15.96/tablet 14% above median
NAC Cholecalciferol 5 mg/mL IM injection 1's x 1 ml 124964 PKR 136.92 PKR 136.92/mL No comparator
NAC Cholecalciferol 5 mg IM injection 5's x 1 ml 124964 PKR 581.28 PKR 116.26/mL No comparator
Niglys Nitroglycerin 2.6 mg Capsule 2x15,s 056165 PKR 313.17 PKR 10.44/capsule No comparator
Niglys Nitroglycerin 6.4 mg Capsule 3x10s 056166 PKR 369.02 PKR 12.30/capsule No comparator
Niglys S.R Nitroglycerin 2.6 mg Sustained-release tablet 2x15s 090197 PKR 313.17 PKR 10.44/tablet 16% above median
Niglys S.R Nitroglycerin 6.4 mg Sustained-release tablet 3x10s 106321 PKR 373.67 PKR 12.46/tablet 10% below median
Oliza 250 Levofloxacin 250 mg Tablet 1x10 038002 PKR 339.10 PKR 33.91/tablet 30% below median
Oliza 500 Levofloxacin 500 mg Tablet 1x10 038003 PKR 678.19 PKR 67.82/tablet 14% below median
Oliza 750 Levofloxacin 750 mg Tablet 1x10 038004 PKR 997.35 PKR 99.74/tablet 7% above median
OM 40mg InjectionRegistry verified Omeprazole as Sodium — — — 129852Official source ↗ No indexed price — —
OM-20 Caps Omeprazole 20 mg Capsule 14s 056163 PKR 287.24 PKR 20.52/capsule Near median
OM-40 Caps Omeprazole 40 mg Capsule 14s 056164 PKR 498.67 PKR 35.62/capsule Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). UniMark Pharmaceuticals Pvt. Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 24, 2026, from https://medinfobase.com/company/unimark-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.